Multi-Omics Profiling and CRISPR Dependency Screening Identify WEE1 Inhibition and Rational BET Inhibitor Combinations as a Therapeutic Strategy for Triple-Negative Breast Cancer
尽管多组学整合与人工智能驱动的药物预测最初强调了 IGF1R/PIK3CA/BET 轴作为三阴性乳腺癌的治疗靶点,但随后的 CRISPR 依赖性筛选和临床验证否定了这些节点,揭示了 WEE1 抑制剂联合 Mitoxantrone 与 BET 抑制剂是更优越且经过功能验证的治疗策略。